Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neuropsychological performance in African children with HIV enrolled in a multicentre anti-retroviral clinical trial

Next Previous
X
Search
Trial Profile

Neuropsychological performance in African children with HIV enrolled in a multicentre anti-retroviral clinical trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Dec 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Nevirapine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms IMPAACT

    • Most Recent Events

    • 18 Dec 2019 Results (n=615) published in the Clinical Infectious Diseases.
    • 07 Mar 2018 Results (n=615) assessing neuropsychological outcomes at enrollment (> 5 yrs age) among HIV+, HIV-uninfected perinatally-exposed (HEU), and HIV unexposed (HU) children from 6 sub-Saharan countries, were presented at the 25th Conference on Retroviruses and Opportunistic infections.
    • 16 Nov 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top